Manufacture

Open-access research paper outlines quality and regulatory considerations for cell therapy manufacturing programs.

The 2025 Power List will be available soon!

In the highly regulated precision medicine development sector, the agility and expertise of a CDMO can make or break a commercial drug candidate.

Off-the-shelf allogeneic CAR-Ts, increased manufacturing productivity led by digital systems; we ask experts about the future of advanced medicine.

With competition for skilled employees in cell and gene therapy manufacturing high, companies need to invest in training and mentorship.

Michiel van den Berg sheds light on the challenges and opportunities facing the industry as it adapts to new materials and regulatory requirements

How hot melt extrusion can enhance drug solubility and bioavailability, offering advantages over spray drying for oral dosage form development.

From cybersecurity challenges and AI-driven decision-making, to making mundane tasks more skillful, robotics is reshaping pharmaceutical operations.

Indian CDMO denies manufacturing drug, contract testing lab pulled up for deficiencies, and lessons learned from Sanofi’s warning letter.

Manufacturing bottlenecks remain a key hurdle in CAR-T therapy. Can automation and digital integration change that?